| Categoría: Revista Española de Cardiología - Blog

Año tras año, las estadísticas muestran un aumento progresivo en el número de implantes de marcapasos permanentes realizados en nuestro medio. Con los sistemas convencionales en uso, las complicaciones relacionadas con los electrodos endovasculares y la bolsa del generador son el motivo más frecuente de morbilidad a corto y largo plazo. Por ello, la llegada de los nuevos sistemas de estimulación, que integran todo el hardware en un dispositivo de inserción percutánea y se alojan completamente en el ventrículo derecho, ha suscitado un gran interés.

| Categoría: Revista Española de Cardiología - Blog

A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents

| Categoría: Revista Española de Cardiología - Blog

Estimados lectores:

Nos alegra hacerte partícipe del dato del factor de impacto (FI) de Rev Esp Cardiol que se acaba de publicar en la última edición del Journal Citation Reports. Recibimos con entusiasmo la puntuación de 3,792 que supone un progreso notable en relación con los datos de factor de impacto previos (FI 2011: 2,530 – FI 2012: 3,204 – FI 2013: 3,342), y coloca a nuestra revista como líder indiscutible de la publicación científica en español, no solo entre las publicaciones médicas, sino en todas las disciplinas.

| Categoría: Revista Española de Cardiología - Blog

Introduction

The randomized CoreValve trial demonstrated that transcatheter aortic valve replacement (TAVR) resulted in significantly lower mortality compared with surgical AVR at 1 year in patients who were at increased risk for surgery. Longer-term outcomes following TAVR with the self- expanding CoreValve are necessary to further validate this survival advantage.

| Categoría: Revista Española de Cardiología - Blog

Introduction

Catheter ablation (CA) represents a valid treatment option in patients with drug-refractory symptomatic atrial fibrillation (AF). The majority of catheter ablation trials have mainly enrolled patients with preserved LVEF and paroxysmal AF. However, a significant number of patients with AF also have heart failure (HF) and rhythm control with antiarrhythmic drugs has not shown satisfactory results in randomized trials both in patients with or without HF. Whether CA is superior to Amiodarone (AMIO) for the treatment of persistent AF in patients with HF is unknown.

| Categoría: Revista Española de Cardiología - Blog

Introduction

The PROMISE trial is an NHLBI-funded randomized comparative effectiveness trial that compared anatomic testing (≥ 64 detector CT angiography) versus functional testing (exercise ECG, stress nuclear, or stress echocardiography) as the initial diagnostic test in patients with new onset symptoms suspicious for coronary artery disease in whom clinicians required diagnostic testing for further evaluation. An economic substudy was conducted to assess economic outcomes and cost effectiveness from a US societal perspective.

| Categoría: Revista Española de Cardiología - Blog

Introduction

There is a need of cardiac protective strategies for high risk patients undergoing cardiac surgery. Remote ischemic conditioning (RIC) supposes a simple non-invasive and low-cost intervention that may improve long-term clinical outcomes in this setting.

| Categoría: Revista Española de Cardiología - Blog

Introduction

Clinical stroke after TAVR is frequent (4-7% at 30 days in RCTs), generally under-reported (17% after SAVR when evaluated by neurologist), confers 3- to 9-fold increased risk of mortality and 50% occurs peri-procedural. Silent stoke affects 58-100% of patients and are associated with neurocognitive decline, dementia and stroke.

| Categoría: Revista Española de Cardiología - Blog

Introduction

Degenerative MR is common, affecting ~600,000 persons in the U.S. Surgery is the standard of care, and is indicated for patients with symptoms or LV dysfunction. However, there are patients in whom the risk of surgery is prohibitive. The Mitraclip system received commercial approval in October 24, 201, being indicated for symptomatic patients with primary MR ≥3 and prohibitive surgical risk. Our objective was to analyze and report the initial commercial experience with the MitraClip System in the U.S.

| Categoría: Revista Española de Cardiología - Blog

Published in The Lancet.

Introduction

The Placement of Aortic Transcatheter Valves (PARTNER) trial showed that mortality at 1 year, 2 years, and 3 years is much the same with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) for high-risk patients with aortic stenosis. We report here the 5-year outcomes.